# Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

Study · id `cardio:ct-nct04952766` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04952766](<https://clinicaltrials.gov/study/NCT04952766>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04952766

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

## Technical summary

Registry record NCT04952766. Allocation not applicable; no masking; primary purpose other. Start 2021-03-26 (actual); primary completion 2022-02-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose other
- Phase: Phase 4
- Enrolled: 196 participants (enrolled count; ClinicalTrials.gov record NCT04952766, source copy `cardio:ctgov-nct04952766-2025-12-23`, retrieved 2026-10-26)
- Started: 2021-03-26 (actual) (ClinicalTrials.gov record NCT04952766, source copy `cardio:ctgov-nct04952766-2025-12-23`, retrieved 2026-10-26)
- Primary completion: 2022-02-06 (actual) (ClinicalTrials.gov record NCT04952766, source copy `cardio:ctgov-nct04952766-2025-12-23`, retrieved 2026-10-26)
- Completion: 2022-02-06 (actual) (ClinicalTrials.gov record NCT04952766, source copy `cardio:ctgov-nct04952766-2025-12-23`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04952766, source copy `cardio:ctgov-nct04952766-2025-12-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04952766-2025-12-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
- Acronym: EREVA
- Condition: Kidney Transplant
- Condition: Myeloma
- Condition: Cancer
- Condition: Hematologic Malignancy
- Condition: Multiple Sclerosis
- Condition: Hypergammaglobulinemia
- Condition: Malignant Tumor
- Condition: Hiv
- Condition: Diabetes Type 2
- Intervention (Biological): Biological samples
- Lead sponsor: Centre Hospitalier Régional d'Orléans
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 674ab26743b3ccaae9013a212226c4e3b08b4ef95d1315d2509ffc18dbba0964
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
